Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Fontolizumab






●العربية
 ●Italiano
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Fontolizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetinterferon gamma
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Molar massca. 150 kg/mol
 ☒NcheckY (what is this?)  (verify)

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]

References

[edit]
  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
  • ^ Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. (February 2010). "Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory Bowel Diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334. S2CID 25337474.
  • ^ Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov
    • Stub icon

    This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e
    • Stub icon

    This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Fontolizumab&oldid=1170236054"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Monoclonal antibodies
     ●Abandoned drugs
     ●Monoclonal antibody stubs
     ●Antineoplastic and immunomodulating drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description is different from Wikidata
     ●Articles with changed CASNo identifier
     ●Chemicals that do not have a ChemSpider ID assigned
     ●Infobox-drug molecular-weight unexpected-character
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without InChI source
     ●Drugs with no legal status
     ●Drugboxes which contain changes to verified fields
     ●Drugboxes which contain changes to watched fields
     ●Drugs that are a monoclonal antibody
     ●All stub articles
      


    ●This page was last edited on 13 August 2023, at 21:54 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki